177 related articles for article (PubMed ID: 16224427)
1. Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research.
Barrett JC; Bennett LM; Fleming LK; Linehan WM; Liotta LA; Rosenberg SA; Petricoin EF; Staudt LM; Thompson TE; Yang JC
Clin Adv Hematol Oncol; 2003 May; 1(5):302-6. PubMed ID: 16224427
[TBL] [Abstract][Full Text] [Related]
2. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
3. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
Christian MC; Pluda JM; Ho PT; Arbuck SG; Murgo AJ; Sausville EA
Semin Oncol; 1997 Apr; 24(2):219-40. PubMed ID: 9129691
[TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
5. Anticancer drug development at the US National Cancer Institute.
Takimoto CH
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S29-33. PubMed ID: 12819935
[TBL] [Abstract][Full Text] [Related]
6. The preclinical new drug research program of the National Cancer Institute.
Driscoll JS
Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
[TBL] [Abstract][Full Text] [Related]
7. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
8. NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide.
Minig L; Trimble EL; Birrer MJ; Kim KY; Takebe N; Abrams JS
Gynecol Oncol; 2010 Feb; 116(2):177-80. PubMed ID: 19889449
[TBL] [Abstract][Full Text] [Related]
9. Small molecules, big players: the National Cancer Institute's Initiative for Chemical Genetics.
Tolliday N; Clemons PA; Ferraiolo P; Koehler AN; Lewis TA; Li X; Schreiber SL; Gerhard DS; Eliasof S
Cancer Res; 2006 Sep; 66(18):8935-42. PubMed ID: 16982730
[TBL] [Abstract][Full Text] [Related]
10. [Cancer research at the transition from bench to bedside].
Wiestler OD; Rautenstrauch J
Med Klin (Munich); 2006 Feb; 101(2):153-9. PubMed ID: 16501913
[TBL] [Abstract][Full Text] [Related]
11. Developing new agents for the treatment of childhood cancer.
Kurmasheva R; Morton C; Houghton PJ
Curr Opin Investig Drugs; 2005 Dec; 6(12):1215-27. PubMed ID: 16372407
[TBL] [Abstract][Full Text] [Related]
12. The NCI Alliance for Nanotechnology in Cancer: achievement and path forward.
Ptak K; Farrell D; Panaro NJ; Grodzinski P; Barker AD
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(5):450-60. PubMed ID: 20552623
[TBL] [Abstract][Full Text] [Related]
13. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
14. Challenges in cancer research and multifaceted approaches for cancer biomarker quest.
Martinkova J; Gadher SJ; Hajduch M; Kovarova H
FEBS Lett; 2009 Jun; 583(11):1772-84. PubMed ID: 19327356
[TBL] [Abstract][Full Text] [Related]
15. Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care.
Ross JS; Ginsburg GS
Expert Rev Mol Diagn; 2002 Nov; 2(6):531-41. PubMed ID: 12465450
[TBL] [Abstract][Full Text] [Related]
16. Progress towards personalized medicine.
Bates S
Drug Discov Today; 2010 Feb; 15(3-4):115-20. PubMed ID: 19914397
[TBL] [Abstract][Full Text] [Related]
17. Toward a molecular classification of cancer.
Weber GF
Toxicology; 2010 Dec; 278(2):195-8. PubMed ID: 19857539
[TBL] [Abstract][Full Text] [Related]
18. Five strategies for accelerating the war on cancer in an era of budget deficits.
Doroshow JH; Croyle RT; Niederhuber JE
Oncologist; 2009 Feb; 14(2):110-6. PubMed ID: 19147688
[TBL] [Abstract][Full Text] [Related]
19. Proteomic approaches for serum biomarker discovery in cancer.
Maurya P; Meleady P; Dowling P; Clynes M
Anticancer Res; 2007; 27(3A):1247-55. PubMed ID: 17593616
[TBL] [Abstract][Full Text] [Related]
20. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.
Bharti A; Ma PC; Salgia R
Mass Spectrom Rev; 2007; 26(3):451-66. PubMed ID: 17407130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
